Aquestive therapeutics announces fda acceptance of new drug application (nda) resubmission for libervant™ (diazepam) buccal film

Warren, n.j., july 19, 2021 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that the u.s. food and drug administration (fda) has accepted for filing the resubmission of the new drug application (nda) for libervant™ (diazepam) buccal film for the management of seizure clusters. the fda has assigned a prescription drug user fee act (“pdufa”) target goal date of december 23, 2021.
AQST Ratings Summary
AQST Quant Ranking